{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "In this single-center, retrospective cohort study"
      },
      "Participants": {
        "score": 2,
        "evidence": "652 patients undergoing elective resection of pancreatic cancer at Heidelberg University Hospital between 2009 and 2016"
      },
      "Intervention": {
        "score": 2,
        "evidence": "divided into two groups: the high-EtCO2 group and the low-EtCO2 group"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The pre-specified primary endpoint was the assessment of recurrence-free survival up to the last known follow-up"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "652 patients undergoing elective resection of pancreatic cancer"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Recurrence-free survival did not differ among the high and low-EtCO2 groups [HR = 1.043 (95% CI: 0.875\u20131.243), log rank test: p = 0.909]"
      },
      "Harms": {
        "score": 1,
        "evidence": "Cardiovascular events, surgical site infections, sepsis, and reoperations during the hospital stay, as well as overall survival were pre-specified secondary outcomes"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}